EUVIMEDEUVIMED entdecken
Crossref

Subclinical myocardial damage after anthracycline chemotherapy in Japanese patients with breast cancer

Kenji Nakatsuma, Neiko Ozasa, Mikiko Ohno, Hiroshi Ishiguro, Manabu Minami, Eiichiro Nishi, Masakazu Toi, Koh Ono, Takeshi Kimura

Journal of Cardiology · 2024

DOI: 10.1016/j.jjcc.2024.03.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiology, 2024. Verfasst von Kenji Nakatsuma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Anthracyclines, Natriuretic Peptide, Brain, Troponin I. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Data on the incidence, timing, and severity of myocardial damage after anthracycline-based chemotherapy (AC) in Japanese patients with breast cancer are limited. METHOD: We evaluated cancer therapy-related cardiac dysfunction (CTRCD) in Japanese women with breast cancer (n = 51) after the first AC according to the definitions of the 2022 European Society of Cardiology onco-cardiology guideline, including assessment of high-sensitivity troponin I (TnI) and B-type natriuretic peptide (BNP) levels. RESULTS: CTRCD was detected in 67 % of the patients (3.9 %, 7.8 %, 9.8 %, 43 %, 37 %, 22 %, 20 %, and 9.8 % of patients at 1 week and 1, 2, 3, 6, 9, 12, and 15 months post-AC, respectively) without significant left ventricular ejection fraction reduction ( 26 pg/mL) were found in 43 % of patients, and elevated BNP levels (≥35 pg/mL) were observed in 22 % of patients during the follow-up period. CONCLUSIONS: Approximately two-thirds of the Japanese patients in this study experienced CTRCD, which was frequently observed at 3 or 6 months post-AC. However, all patients with CTRCD were diagnosed with mild asymptomatic CTRCD. Although, these patients were diagnosed with mild asymptomatic CTRCD, careful long-term follow-up will be required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAnthracyclinesNatriuretic Peptide, BrainTroponin IHumansFemaleMiddle AgedJapanAdultAgedStroke VolumeIncidenceCardiotoxicityEast Asian People

Stichwörter der Autor:innen

AnthracyclineBiomarkersBreast cancer

Substanzen

AnthracyclinesNatriuretic Peptide, BrainTroponin I

Autor:innen und Institutionen

  • Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan.
  • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Electronic address: nei126@kuhp.kyoto-u.ac.jp.
  • Department of Pharmacology, Shiga University of Medical Science, Shiga, Japan.
  • Department of Breast Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
  • Department of Data Science, National Cerebral and Cardiovascular Center, Osaka, Japan.
  • Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Zitieren

APA

Nakatsuma, K., Ozasa, N., Ohno, M., Ishiguro, H., Minami, M., Nishi, E., Toi, M., Ono, K., & Kimura, T. (2024). Subclinical myocardial damage after anthracycline chemotherapy in Japanese patients with breast cancer. Journal of Cardiology. https://doi.org/10.1016/j.jjcc.2024.03.005

Vancouver

Nakatsuma K, Ozasa N, Ohno M, Ishiguro H, Minami M, Nishi E, et al. Subclinical myocardial damage after anthracycline chemotherapy in Japanese patients with breast cancer. Journal of Cardiology. 2024. doi:10.1016/j.jjcc.2024.03.005

BibTeX
@article{Nakatsuma2024,
  author = {Nakatsuma, Kenji and Ozasa, Neiko and Ohno, Mikiko and Ishiguro, Hiroshi and Minami, Manabu and Nishi, Eiichiro and Toi, Masakazu and Ono, Koh and Kimura, Takeshi},
  title = {Subclinical myocardial damage after anthracycline chemotherapy in Japanese patients with breast cancer},
  journal = {Journal of Cardiology},
  year = {2024},
  doi = {10.1016/j.jjcc.2024.03.005}
}
Kostenlos starten →